Impact ledger
Revolution Medicines, Inc. (RVMD): the developments shaping its investment case
Follow the evidence affecting Revolution Medicines, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Revolution Medicines, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-03 · 6 reports
NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data
Channel: Direct positive clinical trial data publication in a prestigious journal (NEJM) for a key pipeline asset (darovasertib in RAS-mutant NSCLC), validating the company's pan-RAS inhibitor platform and increasing confidence in future commercialization.
Bullish· 1-3m
2026-08-27 · 5 reports
FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor
Channel: Direct commercialization of a newly approved, first-in-class drug, leading to immediate revenue generation.
Bullish· 1-3m
Event impact log
11 events mapped to RVMD since 2026-08-26. Evidence through 2026-09-03.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-03 | NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data | Direct positive clinical trial data publication in a prestigious journal (NEJM) for a key pipeline asset (darovasertib in RAS-mutant NSCLC), validating the company's pan-RAS inhibitor platform and increasing confidence in future commercialization. | Bullish | 1-3m | 0.90 |
| 2026-09-03 | Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR | Direct clinical trial success for lead candidate, increasing probability of regulatory approval and future market penetration. | Bullish | 1-3m | 0.90 |
| 2026-09-03 | Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM | Direct validation of clinical pipeline asset, increasing probability of success for future phases and potential market entry. | Bullish | 1-3m | 0.90 |
| 2026-09-03 | NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival | Direct clinical validation of lead drug candidate, increased market confidence in pipeline, potential for accelerated regulatory pathways. | Bullish | 1-3m | 0.90 |
| 2026-09-03 | NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC | Direct clinical trial success, increasing probability of regulatory approval and commercialization. | Bullish | 1-3m | 0.90 |
| 2026-09-03 | NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer | Direct clinical trial success and validation by prestigious publication (NEJM) increasing market confidence in drug pipeline and future commercial prospects. | Bullish | 1-3m | 0.90 |
| 2026-08-27 | FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor | Direct commercialization of a newly approved, first-in-class drug, leading to immediate revenue generation. | Bullish | 1-3m | 0.90 |
| 2026-08-27 | FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer | Direct revenue generation from drug sales, reduced R&D expenses for this indication, potential for expanded indications, improved market perception and valuation multiples. | Bullish | 1-5y | 0.90 |
| 2026-08-27 | FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer | Direct revenue generation from new drug approval, market validation of pipeline, potential for increased market share in oncology. | Bullish | 1-3m | 0.90 |
| 2026-08-27 | FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma | Direct revenue generation from newly approved drug, market validation of pipeline, potential for increased investor interest. | Bullish | 1-3m | 0.90 |
| 2026-08-26 | FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor | Direct revenue generation from new drug approval, market leadership in a novel therapeutic area, potential for pipeline validation. | Bullish | 1-5y | 0.90 |
Continue this research
Build your Revolution Medicines, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the RVMD entity page →